Safety and Tolerability of A3907 in Primary Sclerosing Cholangitis

Status:
Not yet recruiting

Trial end date:
2023-06-17

Target enrollment:

Participant gender:

This study will test a drug called A3907 to see how safe and tolerated it is for treating people with Primary Sclerosing Cholangitis (PSC).

Phase 2

Albireo